Reduced p21(WAF1/CIP1) protein expression is predominantly related to altered p53 in hepatocellular carcinomas

被引：0

作者：

Shi Y.-Z. ^{[1
]}

Hui A.-M. ^{[1
]}

Takayama T. ^{[1
]}

Li X. ^{[1
]}

Cui X. ^{[1
]}

Makuuchi M. ^{[1
]}

机构：

[1] Hepato-Biliary-Pancreatic Surg. Div., Department of Surgery, Graduate School of Medicine, Tokyo 113-0033, 7-3-1 Hongo, BunkyoOku

来源：

British Journal of Cancer | 2000年 / 83卷 / 1期

关键词：

Hepatocellular carcinoma; p27(WAF1/CIP1); p53;

D O I：

10.1054/bjoc.2000.1310

中图分类号：

学科分类号：

摘要：

To investigate the relationship between the expression of p21(WAF1/CIP1) protein and p53 status and the possible role of the two proteins in hepatocellular carcinomas (HCCs), we examined the expression of p21(WAF1/CIP1) and p53 immunohistochemically in 81 tumours from 65 patients with hepatocellular carcinoma. p21(WAF1/CIP1) protein was absent from 59 of 81 tumours (72.8%), and altered p53 expression was found in 43 (53.1%). p21(WAF1/CIP1) expression was significantly associated with p53 status (P = 0.0008); 38 of 59 tumours lacking p21(WAF1/CIP1) protein were accompanied by altered p53 expression. Further analyses showed that p21(WAF1/CIP1) expression was inversely correlated with p53 expression in hepatitis C virus (HCV)-related HCCs, but not in HBV-related hepatocellular carcinomas and hepatocellular carcinomas without viral infection. All 11 tumours with intrahepatic metastasis showed altered p21(WAF1/CIP1) or p53 expression. In contrast, no intrahepatic metastasis was found in any of the 17 tumours without abnormal expression of either of the two proteins. These results suggest that: (1) different modes of p21(WAF1/CIP1) regulation are involved in HCCs differing in their hepatitis viral infection status, and p21(WAF1/CIP1) expression appears to be predominantly related to altered p53 in HCV-related HCCs; (2) disruption of the p53-p21(WAF1/CIP1) cell-cycle-regulating pathway may contribute to malignant progression of HCC. (C) 2000 Cancer Research Campaign.

引用

页码：50 / 55

页数：5

共 42 条

[1]

Cote R.J., Dunn M.D., Chatterjee S.J., Stein J.P., Shi S.R., Tran Q.C., Hu S.X., Xu H.J., Groshen S., Taylor C.R., Skinner D.G., Benedict W.F., Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53, Cancer Res, 58, pp. 1090-1094, (1998)

[2]

Dulic V., Kaufmann W.K., Wilson S.J., Tlsty T.D., Lees E., Harper J.W., Elledge S.J., Reed S.I., p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest, Cell, 76, pp. 1013-1023, (1994)

[3]

El-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., Vogelstein B., WAF1, a potential mediator of p53 tumor suppression, Cell, 75, pp. 817-825, (1993)

[4]

El-Deiry W.S., Harper J.W., O'Connor P.M., Velculescu V.E., Canman C.E., Jackman J., Pietenpol J.A., Burrell M., Hill D.E., Wang Y., Wilman K.G., Mercer W.E., Kastan M.B., Kohn K.W., Elledge S.J., Kinzler K.W., Vogelstein B., WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis, Cancer Res, 54, pp. 1169-1174, (1994)

[5]

Esrig D., Elmajian D., Groshen S., Freeman J.A., Stein J.P., Chen S.-C., Nichols P.W., Skinner D.G., Jones P.A., Cote R.J., Accumulation of nuclear p53 and tumor progression in bladder cancer, N Engl J Med, 331, pp. 1259-1264, (1994)

[6]

Farmer G., Bargonetti J., Zhu H., Friedman P., Prywes R., Prives C., Wild-type p53 activates transcription in vitro, Nature, 358, pp. 83-86, (1992)

[7]

Finlay C.A., Hinds P.W., Tan T.-H., Eliyahu D., Oren M., Levine A.J., Activating mutations for transformation by p53 produce a gene product that forms an hse70-p53 complex with an altered half-life, Mol Cell Biol, 8, pp. 531-539, (1988)

[8]

Furutani M., Arii S., Tanaka H., Mise M., Niwano M., Harada T., Higashitsuji H., Imamura M., Fujita J., Decreased expression and rare somatic mutation of the CIP1/WAF1 gene in human hepatocellular carcinoma, Cancer Lett, 111, pp. 191-197, (1997)

[9]

Gu Y., Turck C.W., Morgan D.O., Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit, Nature, 366, pp. 707-710, (1993)

[10]

Hall P.A., Ray A., Lemoine N.R., Midgley C.A., Krausz T., Lane D.P., p53 immunostaining as a marker of malignant disease in diagnostic cytopathology, Lancet, 338, (1991)

← 1 2 3 4 5 →